Cuprina Holdings (Cayman) Limited - Ordinary shares (CUPR)

For the past two decades, digital cybersecurity has promised to keep pace with hackers, state actors, and insider threats. Yet breach after breach demonstrates the same hard truth: digital defenses inevitably fail when fighting on digital ground .

Peraso Inc. (NASDAQ: PRSO), a pioneer in mmWave wireless technology solutions, announced a new partnership with WeLink Communications, Inc. to expand access to high-speed broadband across dense U.S. metropolitan areas. The collaboration leverages Peraso’s 60 GHz technology to power WeLink’s mesh-based fixed wireless access (FWA) networks, designed to deliver multi-gigabit connectivity to both businesses and residential communities.

SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), the major alliance supporting developing countries in achieving global environmental benefits. 

Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed at helping Cuprina and these institutes jointly produce collagen peptide molecules derived from American bullfrog skin. These peptides, as well as their short chain variants, are widely considered to be useful in the manufacture of an array of medical, pharmaceutical, nutraceutical and cosmetic products.

SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that its indirect 49%-owned associate, Cuprina MENA Co. Ltd, had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company’s MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa (“MENA”) region.

SINGAPORE, May 08, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that it closed the sale of an additional 450,000 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter’s over-allotment option granted in connection with the Company’s initial public offering (“IPO”, together with such over-allotment closing, the “Offering”), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised aggregate gross proceeds of $13,800,000, including the previously announced IPO gross proceeds of $12,000,000, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it had, on April 6, 2025, completed construction of, and obtained ISO 13485 certification and a dealer license for, an operational in-vitro fertilization (“IVF”) media production facility in Singapore.

SINGAPORE, April 11, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the closing of its previously announced initial public offering of an aggregate 3,000,000 Class A Ordinary Shares (“the Offering”) at a price of $4.00 per share (“the Offering Price”) to the public, for a total of $12.0 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.